Surgical Site Infections Pipeline Analysis, 2023 Updates | Latest FDA, EMA, and PMDA Approvals | 3M, Becton, J&J, Belimed AG, Getinge Group, Dickinson Co., Kimberly-Clark Corp

Posted on
by

Surgical Site Infections Pipeline Analysis, 2023 Updates | Latest FDA, EMA, and PMDA Approvals | 3M, Becton, J&J, Belimed AG, Getinge Group, Dickinson Co., Kimberly-Clark Corp
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Surgical Site Infections pipeline constitutes 5+ key companies continuously working towards developing 5+ Surgical Site Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Surgical Site Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Surgical Site Infections Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Surgical Site Infections Market.

 

Some of the key takeaways from the Surgical Site Infections Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Surgical Site Infections treatment therapies with a considerable amount of success over the years. 
  • Surgical Site Infections companies working in the treatment market are Covira Surgical, Sonoran Biosciences, Eupraxia Pharmaceuticals, Destiny Pharma, POLYPID, and others, are developing therapies for the Surgical Site Infections treatment 
  • Emerging Surgical Site Infections therapies in the different phases of clinical trials are- CS-0003, SBG003, EP 201, XF-73, D-PLEX, and others are expected to have a significant impact on the Surgical Site Infections market in the coming years.   
  • In January 2023, PolyPid Ltd. offered a favorable regulatory update concerning D-PLEX100 intended for averting surgical site infections (SSIs) in abdominal colorectal surgeries. After engaging in a recent type D meeting with the US Food and Drug Administration (FDA) regarding the SHIELD I Phase III data, the company has gained a clearer understanding of the regulatory route leading to a potential submission of a New Drug Application (NDA).
  • In August 2022, ADVANZ PHARMA Corp. Limited has inked an exclusive licensing deal with PolyPid Ltd., a late-stage biopharmaceutical company dedicated to enhancing surgical outcomes. This agreement grants ADVANZ PHARMA exclusive rights for the commercialization of PolyPid’s primary drug candidate, D-PLEX100, specifically designed for preventing surgical site infections (SSIs) in abdominal and cardiac surgeries throughout Europe.
  • In April 2022, Mölnlycke has extended its presence in Malaysia through the establishment of a new surgical glove facility. This strategic move aims to bolster the company’s manufacturing capacity, enabling it to meet the rising demand for Biogel gloves while ensuring continued fulfillment of market needs.
  • In March 2022, Invenio has introduced a fresh line of surgical gowns called the V90 surgical gown series.

 

Surgical Site Infections Overview

Surgical site infections (SSIs) are defined as infections that damage the incision or deep tissue at the operation site and can develop up to 30 days following surgery (or up to a year after surgery in patients receiving implants). SSIs continue to pose a serious clinical challenge despite advancements in prevention because they are linked to high rates of morbidity and mortality and place a heavy burden on healthcare resources.

 

Get a Free Sample PDF Report to know more about Surgical Site Infections Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/surgical-site-infections-ssi-pipeline-insight

 

Emerging Surgical Site Infections Drugs Under Different Phases of Clinical Development Include:

  • CS-0003: Covira Surgical
  • SBG003: Sonoran Biosciences
  • EP 201: Eupraxia Pharmaceuticals
  • XF-73: Destiny Pharma
  • D-PLEX: POLYPID

 

Surgical Site Infections Route of Administration

Surgical Site Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

 

Surgical Site Infections Molecule Type

Surgical Site Infections Products have been categorized under various Molecule types, such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

 

Surgical Site Infections Pipeline Therapeutics Assessment

  • Surgical Site Infections Assessment by Product Type
  • Surgical Site Infections By Stage and Product Type
  • Surgical Site Infections Assessment by Route of Administration
  • Surgical Site Infections By Stage and Route of Administration
  • Surgical Site Infections Assessment by Molecule Type
  • Surgical Site Infections by Stage and Molecule Type

 

DelveInsight’s Surgical Site Infections Report covers around 5+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Surgical Site Infections product details are provided in the report. Download the Surgical Site Infections pipeline report to learn more about the emerging Surgical Site Infections therapies

 

Some of the key companies in the Surgical Site Infections Therapeutics Market include:

Key companies developing therapies for Surgical Site Infections are – 3M, Becton, Dickinson and Company, Belimed AG, Getinge Group, Johnson & Johnson, Kimberly-Clark Corporation, Sotera Health, Ansell Limited, Steris Corporation, Lac-Mac Limited, Pacon Manufacturing Corp., American Polyfilm Inc, and others.

 

Surgical Site Infections Pipeline Analysis:

The Surgical Site Infections pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Surgical Site Infections with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Surgical Site Infections Treatment.
  • Surgical Site Infections key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Surgical Site Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Surgical Site Infections market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Surgical Site Infections drugs and therapies

 

Surgical Site Infections Pipeline Market Drivers

  • Rising number of surgeries and the growing geriatric population, increasing concern about hospital acquired infections along with rising incidences of hospital-acquired infections are some of the important factors that are fueling the Surgical Site Infections Market.

 

Surgical Site Infections Pipeline Market Barriers

  • However, lack of awareness regarding infection control measures, difficulty in identifying the site of infection and other factors are creating obstacles in the Surgical Site Infections Market growth.

 

Scope of Surgical Site Infections Pipeline Drug Insight    

  • Coverage: Global
  • Key Surgical Site Infections Companies: Covira Surgical, Sonoran Biosciences, Eupraxia Pharmaceuticals, Destiny Pharma, POLYPID, and others
  • Key Surgical Site Infections Therapies: CS-0003, SBG003, EP 201, XF-73, D-PLEX, and others
  • Surgical Site Infections Therapeutic Assessment: Surgical Site Infections current marketed and Surgical Site Infections emerging therapies
  • Surgical Site Infections Market Dynamics: Surgical Site Infections market drivers and Surgical Site Infections market barriers 

 

Request for Sample PDF Report for Surgical Site Infections Pipeline Assessment and clinical trials

 

Table of Contents

1. Surgical Site Infections Report Introduction

2. Surgical Site Infections Executive Summary

3. Surgical Site Infections Overview

4. Surgical Site Infections- Analytical Perspective In-depth Commercial Assessment

5. Surgical Site Infections Pipeline Therapeutics

6. Surgical Site Infections Late Stage Products (Phase II/III)

7. Surgical Site Infections Mid Stage Products (Phase II)

8. Surgical Site Infections Early Stage Products (Phase I)

9. Surgical Site Infections Preclinical Stage Products

10. Surgical Site Infections Therapeutics Assessment

11. Surgical Site Infections Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Surgical Site Infections Key Companies

14. Surgical Site Infections Key Products

15. Surgical Site Infections Unmet Needs

16 . Surgical Site Infections Market Drivers and Barriers

17. Surgical Site Infections Future Perspectives and Conclusion

18. Surgical Site Infections Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services